Lower Incidence of M184V/I Following Virologic Failure With FTC vs 3TC
{"Image DocumentName": "Lower Incidence of M184V/I Following Virologic Failure With FTC vs 3TC", "Image ImageDescription": "1363 treatment-naive patients experiencing virologic failure in 1 of 3 phase III studies. FTC-301A: FTC QD + ddI + EFV vs d4T + ddI + EFV. GS-903: 3TC BID + TDF + EFV vs 3TC BID + d4T + EFV. GS-934: FTC QD + TDF + EFV vs 3TC BID + ZDV + EFV. Significantly \u2193 rate of M184V/I emergence with FTC QD vs 3TC BID (both in combination with another NRTI and EFV) 3.0. P = Incidence of M184V/I in 3 Pooled Phase III Trials (%) TC, lamivudine; BID, twice daily; d4T, stavudine; ddI, didanosine; EFV, efavirenz; FTC, emtricitabine; NFV, nelfinavir; TDF, tenofovir; ZDV, zidovudine. An analysis of 1363 patients who failed treatment including emtricitabine or lamivudine in 3 large phase III studies suggested that virologic failure was less likely to be associated with the M184V/I mutation in patients who received emtricitabine vs lamivudine. The reasons for this result are not clear, but may be related to the better pharmacology of emtricitabine when used in combination regimens. For more information, please go online to: FTC. (n = 522) 3TC. (n = 841) McColl D, et al. EACS Abstract PE7.3/17.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}